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Introduction: The polymer PEI-MP (polyethyleneimine, functionalised with 
methylphosphonate groups) that might be labelled with 188Re and 99mTc, have a strong 
potential for metabolic radiotherapy and diagnosis, respectively. The aim of this study 
was to evaluate the efficacy of 188Re-PEI-MP as therapeutic agent for bladder carcinoma 
and 99mTc-PEI-MP for its follow up.  
Material and Methods: Cytotoxicity of PEI-MP was investigated in bladder carcinoma 
cell line (CRL-1472) using the MTT test for different concentrations of PEI-MP (1 µM 
to 1000 µM) and incubation times (24h, 48h, 72h and 96h), and flow cytometry for a 
concentration of 1000 µM of PEI-MP (24h). Radiochemical purity of 188Re-PEI-MP and 
99mTc-PEI-MP was achieved using ascending microchromatography. Cellular uptake 
studies were performed using the complexes 188Re-PEI-MP, 99mTc-PEI-MP, Na188ReO4 
and Na99mTcO4. Cell samples were collected during four hours, centrifuged to separate 
supernatant and pellet. Subsequently, the radioactivity of each portion was counted to 
determine percentage of uptake. The in vivo studies were performed using eight groups 
of
 
Balb/c nu/nu mice: four normal groups injected with Na188ReO4, 188Re-PEI-MP, 
Na99mTcO4 and 99mTc-PEI-MP and four with bladder carcinoma xenotransplants injected 
with the same complexes. When tumour reached the appropriate volume, 
radiopharmaceuticals were administered by an intravenous injection in the tail vein (22-
37MBq), with the animal anesthetized and previously placed on the gamma camera 
detector. After injection of the radiopharmaceuticals, were acquired dynamic and static 
images for 2 and 4 hours. For biodistribution proposes, mice were euthanized 2 and 4 
hours after injection and organ samples where weighted and counted in a well-counter 
to obtain percentage injected activity per gram of organ (%ID/g).  
 
  
  
  
 
 
 
 
 
Results: The MTT assay and flow cytometry tests showed that PEI-MP is not cytotoxic. 
The radiochemical purity of 188Re-PEI-MP and 99mTc-PEI-MP was ≥85%. The uptake 
studies demonstrated that the uptake was higher for 188Re-PEI-MP and 99mTc-PEI-MP in 
relation to their controls, and higher for 188Re-PEI-MP e relation to 99mTc-PEI-MP. 
Biodistribution results, with Na188ReO4 and Na99mTcO4, showed a higher uptake by the 
thyroid, bladder and stomach, following a normal biodistribution. The biodistribution 
with 188Re-PEI-MP and 99mTc-PEI-MP showed that the excretion of these complexes 
occurs primarily through the renal system, with a small fraction being eliminated by the 
hepatobilliary system. Tumour/muscle ratio for 188Re-PEI-MP was greater than 1.5. 
Conclusions: Considering the results, 188Re-PEI-MP seems to be promising in the 
treatment of bladder cancer. Following the same biodistribution as 188Re-PEI-MP, 
99mTc-PEI-MP seems to be optimal for diagnosis and follow up of therapy. 
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